ADMA BIOLOGICS, INC. Paid-in-Kind Interest
ADMA BIOLOGICS, INC. (ADMA) reported Paid-in-Kind Interest of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-02-25
- ADMA BIOLOGICS, INC. paid-in-kind interest for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. paid-in-kind interest for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. paid-in-kind interest for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. paid-in-kind interest for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. paid-in-kind interest for fiscal 2025 was $0.00.
- ADMA BIOLOGICS, INC. paid-in-kind interest for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ADMA BIOLOGICS, INC. paid-in-kind interest for fiscal 2023 was $3.84M, a 27.95% increase from fiscal 2022.
- ADMA BIOLOGICS, INC. paid-in-kind interest for fiscal 2022 was $3.00M.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 3 month as first filed | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 6 month as first filed | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 9 month as first filed | Paid-in-Kind Interest 12 month | Paid-in-Kind Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | |||||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $877.00K derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $877.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.87M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $877.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.87M derived: sum of 3 quarters · filed 2026-02-25 | $2.86M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $877.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.87M derived: sum of 2 quarters · filed 2026-02-25 | $2.86M derived: sum of 3 quarters · filed 2026-02-25 | $3.84M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $993.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.98M derived: sum of 2 quarters · filed 2024-11-07 | $2.96M 10-Q · filed 2024-11-07 | $2.96M 10-Q · filed 2023-11-08 | $3.93M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-06-30 | $986.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.97M 10-Q · filed 2024-08-08 | $1.97M 10-Q · filed 2023-08-09 | $2.94M derived: sum of 3 quarters · filed 2025-03-18 | $3.92M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-03-31 | $980.00K 10-Q · filed 2024-05-09 | $979.98K 10-Q · filed 2023-05-10 | $1.95M derived: sum of 2 quarters · filed 2025-03-18 | $2.93M derived: sum of 3 quarters · filed 2025-03-18 | $3.98M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2022-12-31 | $974.07K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.95M derived: sum of 2 quarters · filed 2025-03-18 | $3.00M derived: sum of 3 quarters · filed 2025-03-18 | $3.00M 10-K · filed 2025-03-18 | $3.00M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $978.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.02M derived: sum of 2 quarters · filed 2023-11-08 | $2.02M 10-Q · filed 2023-11-08 | $2.02M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.05M 10-Q · filed 2023-08-09 | $1.05M derived: sum of 3 quarters · filed 2024-02-28 | $1.05M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | |||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |